Announcement PDF RNS Number : 3919O Genedrive PLC 29 May 2020 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Genedrive plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments An event changing the breakdown of voting rights Other (please specify)iii: 3. Details of person subject to the notification obligationiv Name Calculus Capital Limited City and country of registered office (if applicable) 104 Park Street, London, W1K 6NF, UK 4. Full name of shareholder(s) (if different from 3.)v Name Investec Wealth and Investment City and country of registered office (if applicable) 30 Gresham Street, London, EC2V 7QN, UK 5. Date on which the threshold was crossed or reached vi: 28/05/2020 6. Date on which issuer notified (DD/MM/YYYY): 29/05/2020 7. Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8. A) Resulting situation 10.41 % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting 10.41 44,870,071 rights of issuervii on the date on which threshold was crossed or reached Position of previous notification (if applicable) 11.74 11.74 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii A: Voting rights attached to shares Class/type of shares ISIN code (if possible) GB00B1VKB244 Number of voting rightsix % of voting rights Indirect Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) 4,669,282 SUBTOTAL 8. A Direct (Art 10 of Directive 2004/109/EC) (DTR5.2.1) Indirect (Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1) 10.41 4,669,282 10.41 B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of financial instrument Expiration datex Exercise/ Conversion Periodxi Number of voting rights that may be acquired if the instrument is exercised/converted. % of voting rights SUBTOTAL 8. B 1 B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of financial instrument Expiration datex Exercise/ Conversion Physical or cash Period settlement xi SUBTOTAL 8.B.2 xii Number of voting rights % of voting rights 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii X Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold 10. In case of proxy voting, please identify: Name of the proxy holder n/a The number and % of voting rights held n/a The date until which the voting rights will be held n/a 11. Additional informationxvi Place of completion Date of completion London 29/05/2020 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END HOLFLFSIETIAFII